Inovio Pharmaceuticals, Inc.
Inovio is a late-stage biotech company, focused on development and commercialization of immunotherapies targeted against cancer and infectious disease. Our DNA platform functions exclusively in vivo, utilizing next-gen antigen sequencing and delivery to activate a T-cell and antibody driven immune assault on targeted diseases. Inovio immunotherapies are in Phase 2 studies in combination with checkpoint inhibitors for the treatment of HPV-related cancers, advanced bladder cancer, and GBM.